RU2019124709A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2019124709A3 RU2019124709A3 RU2019124709A RU2019124709A RU2019124709A3 RU 2019124709 A3 RU2019124709 A3 RU 2019124709A3 RU 2019124709 A RU2019124709 A RU 2019124709A RU 2019124709 A RU2019124709 A RU 2019124709A RU 2019124709 A3 RU2019124709 A3 RU 2019124709A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762443523P | 2017-01-06 | 2017-01-06 | |
| US62/443,523 | 2017-01-06 | ||
| PCT/US2018/012689 WO2018129397A1 (en) | 2017-01-06 | 2018-01-05 | Compositions and methods related to engineered fc-antigen binding domain constructs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2019124709A RU2019124709A (ru) | 2021-02-08 |
| RU2019124709A3 true RU2019124709A3 (cg-RX-API-DMAC7.html) | 2021-12-21 |
Family
ID=62791385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019124709A RU2019124709A (ru) | 2017-01-06 | 2018-01-05 | КОМПОЗИЦИИ И СПОСОБЫ, СВЯЗАННЫЕ СО СКОНСТРУИРОВАННЫМИ КОНСТРУКЦИЯМИ НА ОСНОВЕ Fc-АНТИГЕНСВЯЗЫВАЮЩЕГО ДОМЕНА |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200040084A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3565595A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2020514301A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018205272A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3049426A1 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2019124709A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018129397A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112912103B (zh) * | 2018-05-21 | 2025-08-29 | 广州邦定生物技术有限公司 | 多价蛋白质复合物 |
| US20210317227A1 (en) * | 2018-07-11 | 2021-10-14 | Momenta Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS |
| CN113164591A (zh) * | 2018-07-11 | 2021-07-23 | 动量制药公司 | 与工程化Fc-抗原结合结构域构建体有关的组合物和方法 |
| MX2021000288A (es) * | 2018-07-11 | 2021-09-08 | Momenta Pharmaceuticals Inc | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente. |
| CA3106254A1 (en) * | 2018-07-11 | 2020-01-16 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc-antigen binding domain constructs |
| JP7476219B2 (ja) | 2019-02-26 | 2024-04-30 | ピエリス ファーマシューティカルズ ゲーエムベーハー | Cd137およびgpc3に特異的な新規融合タンパク質 |
| CN111909268B (zh) * | 2019-05-07 | 2022-04-19 | 北京天成新脉生物技术有限公司 | 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用 |
| EP4031166A1 (en) * | 2019-09-18 | 2022-07-27 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38 |
| WO2021189006A1 (en) * | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iia variants |
| KR102963172B1 (ko) * | 2021-10-22 | 2026-05-18 | 상트네어바이오사이언스 주식회사 | 두개의 Fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도 |
| WO2024219897A1 (ko) | 2023-04-21 | 2024-10-24 | 상트네어바이오사이언스 주식회사 | 두 개의 fab 도메인 및 두 개의 fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도 |
| TW202504932A (zh) | 2023-04-21 | 2025-02-01 | 南韓商百歲生命科學股份有限公司 | 包含兩個fc區域之抗原結合蛋白及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090304715A1 (en) * | 2006-03-03 | 2009-12-10 | Tokyo University Of Science | Modified antibodies with enhanced biological activities |
| WO2008137382A1 (en) * | 2007-04-30 | 2008-11-13 | Centocor, Inc. | Anti-tissue factor antibodies and compositions with enhanced effector function |
| WO2012116926A1 (en) * | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Antigen binding proteins |
| PH12014500220A1 (en) * | 2011-07-27 | 2019-03-22 | Glaxo Group Ltd | Anti-vegf single variable domains fused to fc domains |
| SG11201506451UA (en) * | 2013-03-06 | 2015-09-29 | Merrimack Pharmaceuticals Inc | Anti-c-met tandem fc bispecific antibodies |
| US10858417B2 (en) * | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| SG10201913507SA (en) * | 2014-05-02 | 2020-02-27 | Momenta Pharmaceuticals Inc | Compositions and methods related to engineered fc constructs |
-
2018
- 2018-01-05 US US16/474,572 patent/US20200040084A1/en not_active Abandoned
- 2018-01-05 EP EP18735797.5A patent/EP3565595A4/en not_active Withdrawn
- 2018-01-05 JP JP2019537110A patent/JP2020514301A/ja active Pending
- 2018-01-05 WO PCT/US2018/012689 patent/WO2018129397A1/en not_active Ceased
- 2018-01-05 AU AU2018205272A patent/AU2018205272A1/en not_active Abandoned
- 2018-01-05 CA CA3049426A patent/CA3049426A1/en not_active Abandoned
- 2018-01-05 RU RU2019124709A patent/RU2019124709A/ru unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3565595A1 (en) | 2019-11-13 |
| JP2020514301A (ja) | 2020-05-21 |
| US20200040084A1 (en) | 2020-02-06 |
| CA3049426A1 (en) | 2018-07-12 |
| EP3565595A4 (en) | 2021-03-17 |
| WO2018129397A1 (en) | 2018-07-12 |
| AU2018205272A1 (en) | 2019-07-25 |
| RU2019124709A (ru) | 2021-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019008823A2 (cg-RX-API-DMAC7.html) | ||
| BR112019025875B1 (pt) | Sistema de cilindro com estrutura de ocupação de movimento relativo | |
| BR112020006283B1 (pt) | Placa refinadora, e, refinador para tratamento mecânico de material orgânico/celulósico | |
| BR112020009729B1 (pt) | Inibidores de acss2 e métodos de uso dos mesmos | |
| BR112020008714B1 (pt) | Uso de medicamentos serotoninérgicos para tratar trombocitopenia induzida por vírus | |
| BR112020006992B1 (pt) | Dispositivo de recolhimento e método para o recolhimento de uma embarcação | |
| BR112019023976B1 (pt) | Sistema e método para comunicar dados de saúde em um ambiente de cuidados de saúde | |
| BR112020003314B1 (pt) | Sistema terapêutico transdérmico para administração transdérmica de um agente ativo, seu método de fabricação, usos de emulsificante, e método para estabilizar uma mistura de revestimento bifásica | |
| BR112020003112B1 (pt) | Método de garantir a viabilidade de uma máquina para uma tarefa agendada | |
| BR112020002577B1 (pt) | Método de melhoria de rendimento de centrifugação dupla para purificação de óleo nutritivo | |
| BR112019016885B1 (pt) | Remodelagem de imagem integrada e codificação de vídeo | |
| BR112020001354B1 (pt) | Método, em uma primeira estação base, para suportar posicionamento de um dispositivo móvel e primeira estação base para suportar posicionamento de um dispositivo móvel | |
| BR112019027876B1 (pt) | Método de codificação para uma comunicação sem fio, codificador, método de decodificação, decodificador, aparelho de comunicação, meio de armazenagem legível por computador, e sistema de comunicações | |
| BR112019026818B1 (pt) | Método de codificação, método de decodificação, aparelho, aparelho de comunicações, terminal, estação base e mídia legível por computador | |
| BR112019026880B1 (pt) | Método de comunicação, método para receber dados, e, dispositivo | |
| BR112019023944B1 (pt) | Combinação farmacêutica para o tratamento de um câncer | |
| BR112019021396B1 (pt) | Processo para fabricação de pululano | |
| BR102018003507B1 (pt) | Sistema de isolamento de tensão de tambor de guincho | |
| BR112019016182B1 (pt) | Método para diagnosticar risco de revisão relacionado a implante | |
| BR112019014127B1 (pt) | Composição farmacêutica para tratamento de tumores | |
| BR112019017156B1 (pt) | Dispositivo, sistema e método de gerenciamento de recepção de pedido, e, meio de armazenamento legível por computador | |
| BR102017026429B1 (pt) | Método de extração subsequente de ácidos graxos e dna genômico a partir de dípteros | |
| BR112020009084B1 (pt) | Método de operação de um nó de rádio alvo, nó de rádio alvo, método de operação de um nó de rádio de transmissão, nó de rádio de transmissão, e, meio de armazenamento não transitório legível por computador | |
| BR112020008456B1 (pt) | Terminal e método de transmissão para um terminal | |
| BR112020004962B1 (pt) | Terminal que controla a recepção de um sinal de referência de um sistema sem fio com base em informações que permitem a multiplexação de frequências entre um sinal de dados e um sinal de referência |